## Abstract Expression of an estrogen receptor α (ER) transgene in hormone independent breast cancer and normal breast epithelial cells arrests cell cycling when estradiol is added. Although endogenously expressed ER does not typically affect estradiol‐induced cell cycling of hormone dependent brea
Estrogen-dependent regulation of ornithine decarboxylase in breast cancer cells through activation of nongenomic cAMP-dependent pathways
✍ Scribed by Chunhua Qin; Ismael Samudio; Sharon Ngwenya; Stephen Safe
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 225 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20030
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
17β‐Estradiol (E2) induces ornithine decarboxylase (ODC) activity in several E2‐responsive tissues/cells, and this study investigated the mechanism of hormone‐induced transactivation in MCF‐7 human breast cancer cells. E2‐induced reporter gene (luciferase) activity in MCF‐7 cells transfected with a construct (pODC1) containing the −164 to +29 region of the human ODC gene promoter linked to bacterial luciferase. This promoter sequence contains GC‐rich Sp1 binding sites, CAAT, LSF, cAMP response element (CRE), and TATA motifs. Deletion and mutational analysis of the ODC promoter showed that both CAAT and LSF sites were required for hormone‐induced transactivation. Gel mobility shift and DNA footprinting assays indicated that NFYA and LSF bound the CAAT and LSF motifs, respectively, and GAL4‐NFYA/GAL4‐LSF chimeras were also activated by E2, 8‐bromo‐cAMP, and protein kinase A (PKA) expression plasmid. However, E2‐induced transactivation of GAL4‐NFYA and GAL4‐LSF was blocked by the PKA inhibitor SQ22356 indicating that the mechanism of ODC induction by E2 involves upregulation of cAMP/PKA through nongenomic pathways of estrogen action. © 2004 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Multidrug resistance (MDR) is a major obstacle in cancer chemotherapy and its inhibition is an effective way to reverse cancer drug resistance. In the present study, we investigated that puerarin, a natural isoflavonoid from Pueraria lobata, down-regulated MDR1 expression in MCF-7/adriamycin (MCF-7/